Press Releases and News

Landos Biopharma to Present at Upcoming Investor Conferences

March 07 2019

Landos Biopharma to Present at Upcoming Investor Conferences

BLACKSBURG, VIRGINIA, March 7, 2019 – Landos Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of safer and more effective first-in-class oral therapeutics for patients with autoimmune diseases, announced that the Chairman and CEO, Dr. Josep Bassaganya-Riera, will present a company update at the following conferences:

Cowen and Company 39th Annual Healthcare Conference

Tuesday, March 12th at 11:00 a.m. ET

Webcast: http://wsw.com/webcast/cowen52/lans/

Needham & Company 18th Annual Healthcare Conference

Tuesday, April 9th at 11:40 a.m. ET

Webcast: http://wsw.com/webcast/needham90/lans/


BioCentury
Future Leaders in Biotech Conference

Friday, April 12th

The Cowen and Needham presentations will be webcast live at the links shown above and will be archived following the presentation on the Landos website.

“As we continue to build our financial position, we are excited to present Landos’ therapeutic development pipeline for autoimmune diseases and clinical development program
in inflammatory bowel disease (IBD) at these important investment conferences,” said Dr. Josep Bassaganya-Riera, Chairman and CEO. “Our lead compound, BT-11 is a first-in-class, oral, gut-restricted, investigational new drug for Crohn’s Disease (CD) and Ulcerative Colitis (UC) that has the potential to disrupt the current IBD treatment paradigm and address an unmet clinical need for safer and more effective oral therapeutics for IBD. We completed our Phase 1 clinical trial in 2018 and initiated our global Phase 2 program for UC in the US and Europe.”

About Landos Biopharma

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company has completed Phase 1 clinical testing and initiated a Phase 2 clinical program for BT-11 for treatment of UC and CD in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which will advance to IND in 2019. Landos is headquartered in Blacksburg, VA. For more information, please visit www.landosbiopharma.com or contact info@landosbiopharma.com or follow us @Landosbio.

Company Contacts:


Landos Biopharma:

Josep Bassaganya-Riera

540.218.1767

jbr@landosbiopharma.com

For Media Requests:

Sharon Correia

LaVoieHealth Science

617.412.8779

scorreia@lavoiehealthscience.com